In a patient with Bipolar I disorder in a mixed episode for two months who is taking aripiprazole (Abilify) and reports worsening mood and increased suicidal thoughts, what is the appropriate management?

Discontinue Aripiprazole Immediately

Aripiprazole must be stopped immediately in this patient reporting worsening mood and increased suicidal thoughts. The FDA drug label explicitly warns that antipsychotics like aripiprazole can cause emergence or worsening of suicidal ideation, particularly during early treatment phases, and recommends considering discontinuation when patients experience persistently worse depression or emergent suicidality 1.

Why This Is Critical

The patient's report of worsening mood and increased suicidal ideation represents a potentially life-threatening adverse reaction. The FDA label specifically states: "Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality" 1. This is not a wait-and-see situation.

Additionally, aripiprazole can cause akathisia (inner restlessness) in up to 18% of bipolar patients, which can manifest as increased anxiety and suicidal thoughts 2. This side effect may be particularly severe in mixed episodes and can be mistaken for worsening psychiatric symptoms rather than recognized as a medication side effect.

Immediate Management Steps

Safety assessment first:

• Assess current suicide risk (plan, intent, means, protective factors)
• Consider hospitalization if acute risk is present
• Remove access to lethal means
• Establish close monitoring (daily contact minimum)

Medication changes:

• Stop aripiprazole immediately
• Do NOT taper - the priority is removing the offending agent

Alternative Treatment Options

For a bipolar I mixed episode after aripiprazole failure with suicidal ideation:

First-line alternatives include:

1. Lithium - Has the strongest evidence for reducing long-term suicide risk in bipolar disorder, though not rapid-acting 3. This should be strongly considered given the suicidality history.

2. Divalproex/Valproate - Has evidence for efficacy in mixed episodes and may be particularly appropriate here 4.

3. Other atypical antipsychotics with mixed episode data:

   • Cariprazine (strong evidence for mixed features) 4
   • Olanzapine (evidence for acute and maintenance treatment of mixed features) 4
   • Asenapine or ziprasidone (evidence for mixed presentations) 4

Critical consideration: Given the patient's suicidal ideation, lithium should be strongly prioritized despite its slower onset, as it has unique anti-suicidal properties not shared by other mood stabilizers 3. Combine with a second agent if needed for more rapid symptom control.

Monitoring After Discontinuation

• Daily contact for first week minimum
• Weekly visits for first month
• Specifically assess for:
  • Suicidal ideation intensity and frequency
  • Akathisia symptoms (may persist briefly after stopping)
  • Mixed episode symptoms (irritability, racing thoughts, depressed mood, energy changes)
  • Sleep patterns

Common Pitfall to Avoid

Do not assume the suicidal thoughts are "just the bipolar disorder." The temporal relationship between starting aripiprazole and worsening suicidality, combined with the patient's own attribution, strongly suggests a medication-induced effect. The FDA specifically warns about this risk 1, and case reports document this exact presentation with aripiprazole in bipolar patients 2. Trust the patient's report and act accordingly.

The evidence shows bipolar patients have 8.66 times higher risk of suicide than the general population 5, making aggressive intervention essential when any treatment worsens suicidality.